Aditxt Therapeutics is a biotechnology company that develops a novel nucleic acid-based technology.
Aditxt Therapeutics has raised $1.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2024.
Aditxt Therapeutics's investors include U.S. Department of War.
Aditxt Therapeutics is headquartered in Loma Linda, United States.
Aditxt Therapeutics is a biotechnology company that develops a novel nucleic acid-based technology.
Aditxt Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aditxt Therapeutics — Funding & Investors." VCBacked, August 9, 2024, https://www.vcbacked.co/company/aditxt-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). Aditxt Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/aditxt-therapeutics
{{cite web |title=Aditxt Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aditxt-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated